

# Frank G Sandmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/306703/publications.pdf>

Version: 2024-02-01

22  
papers

457  
citations

933447

10  
h-index

794594

19  
g-index

28  
all docs

28  
docs citations

28  
times ranked

600  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid COVID-19 vaccine rollout: immense success but challenges ahead. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 302-304.	9.1	11
2	Augmenting contact matrices with time-use data for fine-grained intervention modelling of disease dynamics: A modelling analysis. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1704-1715.	1.5	4
3	Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region: a mathematical modelling study. <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100267.	5.6	24
4	Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional Comparison With Controls. <i>Clinical Infectious Diseases</i> , 2022, 75, e962-e973.	5.8	32
5	Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis. <i>Lancet Regional Health - Europe</i> , The, 2022, 17, 100381.	5.6	15
6	The impact of COVID-19 vaccination in prisons in England and Wales: a metapopulation model. <i>BMC Public Health</i> , 2022, 22, 1003.	2.9	4
7	The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 962-974.	9.1	117
8	How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations. <i>Value in Health</i> , 2021, 24, 1391-1399.	0.3	1
9	Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation. <i>Value in Health</i> , 2020, 23, 309-318.	0.3	7
10	Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. <i>BMC Medicine</i> , 2020, 18, 38.	5.5	52
11	Optimizing Benefits of Testing Key Workers for Infection with SARS-CoV-2: A Mathematical Modeling Analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 3196-3203.	5.8	6
12	Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-86.	2.8	16
13	O06.4â€¦Efficacy and cost-effectiveness of qHPV vaccine with imiquimod or podophyllotoxin for patients with anogenital warts (HIPvac). , 2019, , .		0
14	Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients. <i>Clinical Infectious Diseases</i> , 2018, 67, 693-700.	5.8	28
15	Estimating the opportunity costs of bedâ€¦days. <i>Health Economics (United Kingdom)</i> , 2018, 27, 592-605.	1.7	31
16	Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants. <i>MDM Policy and Practice</i> , 2018, 3, 238146831775192.	0.9	1
17	The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 475-486.	1.4	10
18	Burden, duration and costs of hospital bed closures due to acute gastroenteritis in England per winter, 2010/11â€¦2015/16. <i>Journal of Hospital Infection</i> , 2017, 97, 79-85.	2.9	16

#	ARTICLE	IF	CITATIONS
19	Letters and debate. Society and Economy, 2014, 36, 427-433.	0.3	0
20	Factors that led to the implementation of the efficiency frontier approach in health economic evaluation in Germany: Do not avoid the elephant in the room. Comment on Klingler et al. (Health) Tj ETQq0 0 0 rgB10/Overlook 10 Tf 50	0.0	0
21	Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Health Policy, 2013, 112, 285-296.	3.0	6
22	Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics, 2013, 31, 781-797.	3.3	26